Angel Adegbesan

5 days ago | bloomberg.com | Angel Adegbesan

The Sarepta Therapeutics headquarters in Cambridge, Massachusetts, in 2019. (Bloomberg) -- Sarepta Therapeutics Inc. capped its worst week in four years as disappointing earnings and regulatory fears hit the drugmaker’s shares. The pain started Tuesday, when Sarepta sank 27% after the commissioner for the Food and Drug Administration named a new regulator that was seen as a vocal critic of the company and its lead medicine, Elevidys.

3 weeks ago | news.bloombergtax.com | Angel Adegbesan

XYour Choices Regarding Cookies and IdentifiersWe and our 150 third party partners use cookies and similar technologies ("Cookies") and hashed identifiers (e.g., a hashed version of your name, email address or phone number) to help us identify you on our site and third-party sites and to process certain information, such as your IP address and digital identifiers, to analyze site usage and provide you with relevant advertisements and content.

3 weeks ago | news.bloomberglaw.com | Angel Adegbesan

Makers of gene therapies and drugs for rare diseases are rallying on Monday after FDA Commissioner commented on drug approvals in an interview over the weekend that analysts view as positive for the sector. • RBC Capital Markets,• Notes Makary remains a proponent of expedited drug approvals and his comments suggest he “may not dramatically break from this trend of biomarker-based accelerated approvals followed by confirmatory studies”• This is potentially positive for “PTCT, SRPT, ...

1 month ago | news.bloombergtax.com | Angel Adegbesan

Shares of several biotechs developing obesity drugs rallied on Monday after Pfizer Inc. halted development of its closely watched experimental pill, as investors bet that the setback could spur dealmaking by Pfizer. Viking Therapeutics Inc.jumped nearly 11%, while Structure Therapeutics Inc. climbed around 19% and Terns Pharmaceuticals Inc. rose 7.9%. Metsera Inc., meanwhile, surged around 30%. “Could Pfizer acquire Viking or one of those other guys?

1 month ago | bloomberg.com | Angel Adegbesan

The Pfizer research and manufacturing site in Andover, Massachusetts. (Bloomberg) -- Shares of several biotechs developing obesity drugs rallied on Monday after Pfizer Inc. halted development of its closely watched experimental pill, as investors bet that the setback could spur dealmaking by Pfizer. Viking Therapeutics Inc. jumped nearly 11%, while Structure Therapeutics Inc. climbed around 19% and Terns Pharmaceuticals Inc. rose 7.9%. Metsera Inc., meanwhile, surged around 30%.